胃癌新辅助放化疗TOPGEAR国际3期临床试验中质量保证的可行性(AGITG/TROG/NHMRC CTC/EORTC/CCTG组间试验)
TOPGEAR 3期试验假设术前放化疗加入围手术期化疗可改善胃癌生存,因胃照射复杂实施了全面放疗质量保证(RTQA)。RTQA对前5例实时进行、后续三分之一病例抽检,203例中200例(99%)治疗前通过,低容量中心需重新提交比例较高但未达统计学显著。
要点
- RTQA初始通过率为72%,28%病例需重新提交,最终99%治疗前通过。
- 低容量中心需重新提交44/136(33%)vs 高容量中心13/67(18%),P=0.078,未达统计学显著。
- 所有需重新提交病例均至少调整临床靶区一方面,十二指肠覆盖不足最常见(主要违规53%,次要违规25%)。
核心结论
- 在大型多中心试验中,RTQA可行且能有效实现高质量治疗计划。
- 应持续开展教育以确保整个研究期间质量一致。
研究设计与样本
- TOPGEAR为3期临床试验,假设术前放化疗加入围手术期化疗可改善胃癌患者生存。
- RTQA对每个中心前5例随机至放化疗组患者在治疗前实时进行,达到可接受质量后对后续三分之一病例完成RTQA。
- RTQA包括评估临床靶区与危及器官勾画以及放疗计划参数。
- 采用Fisher精确检验比较高容量中心(入组20例及以上)与低容量中心的方案违规情况。
主要发现
- TOPGEAR入组574例患者,其中286例随机至术前放化疗组,203例(71%)纳入RTQA。
- 203例中67例(33%)来自高容量中心,136例(67%)来自低容量中心。
- RTQA初始通过率为72%,总计28%病例需重新提交。
- 203例中200例(99%)在治疗前通过RTQA。
- 低容量中心病例需重新提交更频繁(44/136[33%] vs 13/67[18%];P=0.078),随时间推移需重新提交比例无变化。
关键数值与推荐
- 所有需重新提交病例均需至少调整临床靶区的一方面。
- 十二指肠覆盖不足最常见(主要违规53%,次要违规25%)。
- 其余病例的重新提交由勾画或计划质量不佳触发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The TOPGEAR phase 3 trial hypothesized that adding preoperative chemoradiation therapy (CRT) to perioperative chemotherapy will improve survival in patients with gastric cancer. Owing to the complexity of gastric irradiation, a comprehensive radiation therapy quality assurance (RTQA) program was implemented. Our objective is to describe the RTQA methods and outcomes. METHODS AND MATERIALS: RTQA was undertaken in real time before treatment for the first 5 patients randomized to CRT from each center. Once acceptable quality was achieved, RTQA was completed for one-third of subsequent cases. RTQA consisted of evaluating (1) clinical target volume and organ-at-risk contouring and (2) radiation therapy planning parameters. Protocol violations between high- (20+ patients enrolled) and low-volume centers were compared using the Fisher exact test. RESULTS: TOPGEAR enrolled 574 patients, of whom 286 were randomized to receive preoperative CRT and 203 (71%) were included for RTQA. Of these, 67 (33%) and 136 (67%) patients were from high- and low-volume centers, respectively. The initial RTQA pass rate was 72%. In total, 28% of cases required resubmission. In total, 200 of 203 cases (99%) passed RTQA before treatment. Cases from low-volume centers required resubmission more often (44/136 [33%] vs 13/67 [18%]; P = .078). There was no change in the proportion of cases requiring resubmission over time. Most cases requiring resubmission had multiple protocol violations. At least 1 aspect of the clinical target volume had to be adjusted in all cases. Inadequate coverage of the duodenum was most common (53% major violation, 25% minor violation). For the remaining cases, the resubmission process was triggered secondary to poor contour/plan quality. CONCLUSIONS: In a large multicenter trial, RTQA is feasible and effective in achieving high-quality treatment plans. Ongoing education should be performed to ensure consistent quality during the entire study period.
引用
- Lukovic J, Moore AJ, Lee MT, et al. The Feasibility of Quality Assurance in the TOPGEAR International Phase 3 Clinical Trial of Neoadjuvant Chemoradiation Therapy for Gastric Cancer (an Intergroup Trial of the AGITG/TROG/NHMRC CTC/EORTC/CCTG). Int J Radiat Oncol Biol Phys. 2023. PMID: 37393022. doi:10.1016/j.ijrobp.2023.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。